RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+4.51%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.46B
AUM Growth
-$315M
(-4.7%)
Cap. Flow
+$257M
Cap. Flow
% of AUM
3.98%
Top 10 Holdings %
Top 10 Hldgs %
48.84%
Holding
76
New
7
Increased
23
Reduced
12
Closed
8
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$426M |
| 2 |
Insmed
INSM
|
$119M |
| 3 |
Dyne Therapeutics
DYN
|
$116M |
| 4 |
Intuitive Surgical
ISRG
|
$46M |
| 5 |
Glaukos
GKOS
|
$38.8M |
Top Sells
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$157M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$149M |
| 3 |
Stryker
SYK
|
$115M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$94M |
| 5 |
Thermo Fisher Scientific
TMO
|
$64.2M |
Sector Composition
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Intuitive Surgical
ISRG
$158B
| $90.1M | 1.39% |
202,456
+103,456
| +105% | +$46M |
|
27
Arvinas
ARVN
$580M
| $79M | 1.22% |
2,967,897
-330,000
| -10% | -$8.78M |
|
28
Spyre Therapeutics
SYRE
$1.02B
| $76.6M | 1.19% |
3,258,360
+1,025,600
| +46% | +$24.1M |
|
|
CRGX
29
DELISTED
CARGO Therapeutics
CRGX
| $67M | 1.04% |
4,078,122
+342,503
| +9% | +$5.62M |
|
30
UroGen Pharma
URGN
$896M
| $59.7M | 0.92% |
3,557,347
+300,000
| +9% | +$5.03M |
|
|
SAGE
31
DELISTED
Sage Therapeutics
SAGE
| $59.5M | 0.92% |
5,480,577
| – | – |
|
32
89bio
ETNB
$1.37B
| $59.1M | 0.92% |
7,378,548
| – | – |
|
33
Stoke Therapeutics
STOK
$1.08B
| $57.1M | 0.88% |
4,224,838
| – | – |
|
34
Orchestra BioMed
OBIO
$147M
| $45.8M | 0.71% |
5,620,640
| – | – |
|
|
35
Glaukos
GKOS
$5.42B
| $45.7M | 0.71% |
386,291
+327,500
| +557% | +$38.8M |
|
36
CG Oncology
CGON
$2.19B
| $42.4M | 0.66% |
1,344,074
+930,404
| +225% | +$29.4M |
|
37
Taysha Gene Therapies
TSHA
$791M
| $42.1M | 0.65% |
18,800,299
+207,114
| +1% | +$464K |
|
38
Neurogene
NGNE
$284M
| $39M | 0.6% |
1,070,565
+301,443
| +39% | +$11M |
|
39
GH Research
GHRS
$870M
| $38.8M | 0.6% |
3,327,129
| – | – |
|
40
Vericel Corp
VCEL
$1.69B
| $36.8M | 0.57% |
801,397
-805,000
| -50% | -$36.9M |
|
41
Fulcrum Therapeutics
FULC
$353M
| $36.2M | 0.56% |
5,845,956
| – | – |
|
42
Cullinan Oncology
CGEM
$456M
| $18.4M | 0.28% |
+1,052,630
| New | +$18.4M |
|
43
Dianthus Therapeutics
DNTH
$781M
| $17.3M | 0.27% |
666,667
| – | – |
|
44
Roivant Sciences
ROIV
$8.6B
| $15.4M | 0.24% |
1,454,273
| – | – |
|
|
LENZ
45
LENZ Therapeutics
LENZ
$1.12B
| $14.9M | 0.23% |
863,389
| – | – |
|
|
TEM
46
Tempus AI, Inc. Class A Common Stock
TEM
$13.3B
| $14M | 0.22% |
+400,000
| New | +$14M |
|
47
Kyverna Therapeutics
KYTX
$161M
| $13.9M | 0.22% |
1,852,711
| – | – |
|
48
ESSA Pharma
EPIX
$11.2M
| $12.1M | 0.19% |
2,298,662
| – | – |
|
49
Replimune Group
REPL
$460M
| $10.2M | 0.16% |
+1,133,787
| New | +$10.2M |
|
50
10x Genomics
TXG
$1.66B
| $9.78M | 0.15% |
502,856
-1,052,000
| -68% | -$20.5M |
|